89bio, Inc. Overview
Pro stress-test →89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG).
Strategic Profile
Pro stress-test →Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company agreed to be acquired by Roche at a price of $14.50 per share in cash at closing in September 2025, representing a premium of approximately 79% to 89bio's closing stock price on September 17, 2025.
Competitive Landscape
Pro stress-test →Competing in the FGF21 analog and metabolic disease space against other clinical-stage and late-stage biotech companies developing therapies for MASH and cardiometabolic diseases. Key competitors include other FGF21 programs and GLP-1-based obesity/metabolic therapies in development.
Industry Context
89bio, Inc. operates in Biotechnology / Biopharmaceuticals.
Key facts
Founded: 2018 · Headquarters: San Francisco, US · Market cap: N/A